Randomized comparison of interferon α and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon α and hydroxyurea
The optimum treatment conditions of interferon (IFN) α therapy in chronic myeloid leukemia (CML) are still controversial. To evaluate the role of hydroxyurea (HU) for the outcome of IFN therapy, we conducted a randomized trial to compare the combination of IFN and HU vs HU monotherapy (CML-study II)...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
29 July 2003
|
| In: |
Leukemia
Year: 2003, Jahrgang: 17, Heft: 8, Pages: 1529-1537 |
| ISSN: | 1476-5551 |
| DOI: | 10.1038/sj.leu.2403006 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/sj.leu.2403006 Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/2403006 
|
| Verfasserangaben: | R. Hehlmann, U. Berger, M. Pfirrmann, A. Hochhaus, G. Metzgeroth, O. Maywald, J. Hasford, A. Reiter, D.K. Hossfeld, H.-J. Kolb, H. Löffler, H. Pralle, W. Queißer, M. Griesshammer, C. Nerl, R. Kuse, A. Tobler, H. Eimermacher, A. Tichelli, C. Aul, M. Wilhelm, J.T. Fischer, M. Perker, C. Scheid, M. Schenk, J. Weiß, C.R. Meier, S. Kremers, L. Labedzki, T. Schmeiser, H.-P. Lohrmann, H. Heimpel and the German CML-Study Group |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 180171715X | ||
| 003 | DE-627 | ||
| 005 | 20220820182610.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220513s2003 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/sj.leu.2403006 |2 doi | |
| 035 | |a (DE-627)180171715X | ||
| 035 | |a (DE-599)KXP180171715X | ||
| 035 | |a (OCoLC)1341459993 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hehlmann, Rüdiger |d 1941- |e VerfasserIn |0 (DE-588)1037003489 |0 (DE-627)751737879 |0 (DE-576)390939463 |4 aut | |
| 245 | 1 | 0 | |a Randomized comparison of interferon α and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II) |b prolongation of survival by the combination of interferon α and hydroxyurea |c R. Hehlmann, U. Berger, M. Pfirrmann, A. Hochhaus, G. Metzgeroth, O. Maywald, J. Hasford, A. Reiter, D.K. Hossfeld, H.-J. Kolb, H. Löffler, H. Pralle, W. Queißer, M. Griesshammer, C. Nerl, R. Kuse, A. Tobler, H. Eimermacher, A. Tichelli, C. Aul, M. Wilhelm, J.T. Fischer, M. Perker, C. Scheid, M. Schenk, J. Weiß, C.R. Meier, S. Kremers, L. Labedzki, T. Schmeiser, H.-P. Lohrmann, H. Heimpel and the German CML-Study Group |
| 246 | 3 | 3 | |a Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II) |
| 264 | 1 | |c 29 July 2003 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 13.05.2022 | ||
| 520 | |a The optimum treatment conditions of interferon (IFN) α therapy in chronic myeloid leukemia (CML) are still controversial. To evaluate the role of hydroxyurea (HU) for the outcome of IFN therapy, we conducted a randomized trial to compare the combination of IFN and HU vs HU monotherapy (CML-study II). From February 1991 to December 1994, 376 patients with newly diagnosed CML in chronic phase were randomized. In all, 340 patients were Ph/BCR-ABL positive and evaluable. Randomization was unbalanced 1:2 in favor of the combination therapy, since study conditions were identical to the previous CML-study I and it had been planned in advance to add the HU patients of study I (n=194) to the HU control group. Therefore, a total of 534 patients were evaluable (226 patients with IFN/HU and 308 patients with HU). Analyses were according to intention-to-treat. Median observation time of nontransplanted living patients was 7.6 years (7.9 years for IFN/HU and 7.3 years for HU). The risk profile (new CML score) was available for 532 patients: 200 patients (38%) were low, 239 patients (45%) intermediate, and 93 patients (17%) high risk. Complete hematologic response rates were higher in IFN/HU-treated patients (59 vs 32%). Of 169 evaluable IFN/HU-treated patients (75%), 104 patients (62%) achieved a cytogenetic response that was complete in 12% (n=21), major in 14% (n=24), and at least minimal in 35% (n=59). Of the 534 patients, 105 (20%) underwent allogeneic stem cell transplantation in first chronic phase. In the low-risk group, 65 of 200 patients were transplanted (33%), 30 (13%) in the intermediate-risk group, and nine (10%) in the high-risk group. Duration of chronic phase was 55 months for IFN/HU and 41 months for HU (P<0.0001). Median survival was 64 months for IFN/HU and 53 months for HU-treated patients (P=0.0063). We conclude that IFN in combination with HU achieves a significant long-term survival advantage over HU monotherapy. In view of the data of CML-study I, these results suggest that IFN/HU is also superior to IFN alone. HU should be combined with IFN in IFN-based therapies and for comparisons with new therapies. | ||
| 650 | 4 | |a Cancer Research | |
| 650 | 4 | |a general | |
| 650 | 4 | |a Hematology | |
| 650 | 4 | |a Intensive / Critical Care Medicine | |
| 650 | 4 | |a Internal Medicine | |
| 650 | 4 | |a Medicine/Public Health | |
| 650 | 4 | |a Oncology | |
| 700 | 1 | |a Berger, Ute |e VerfasserIn |0 (DE-588)1255399929 |0 (DE-627)1799635341 |4 aut | |
| 700 | 1 | |a Pfirrmann, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hochhaus, Andreas |d 1959- |e VerfasserIn |0 (DE-588)1107039339 |0 (DE-627)863321976 |0 (DE-576)474976130 |4 aut | |
| 700 | 1 | |a Metzgeroth, Georgia |d 1972- |e VerfasserIn |0 (DE-588)1051897661 |0 (DE-627)786986832 |0 (DE-576)407534075 |4 aut | |
| 700 | 1 | |a Maywald, O. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hasford, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Reiter, Andreas |d 1964- |e VerfasserIn |0 (DE-588)172629551 |0 (DE-627)697563766 |0 (DE-576)133488594 |4 aut | |
| 700 | 1 | |a Hossfeld, D. K. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kolb, H.-J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Löffler, H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pralle, H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Queißer, Wolfgang |d 1936- |e VerfasserIn |0 (DE-588)115699325 |0 (DE-627)077414225 |0 (DE-576)162635923 |4 aut | |
| 700 | 1 | |a Griesshammer, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nerl, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kuse, R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tobler, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Eimermacher, H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tichelli, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Aul, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wilhelm, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fischer, J. T. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Perker, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Scheid, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schenk, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Weiß, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Meier, C. R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kremers, S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Labedzki, L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schmeiser, T. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lohrmann, H.-P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Heimpel, H. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia |d London : Springer Nature, 1997 |g 17(2003), 8, Seite 1529-1537 |h Online-Ressource |w (DE-627)32046699X |w (DE-600)2008023-2 |w (DE-576)094139733 |x 1476-5551 |7 nnas |a Randomized comparison of interferon α and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II) prolongation of survival by the combination of interferon α and hydroxyurea |
| 773 | 1 | 8 | |g volume:17 |g year:2003 |g number:8 |g pages:1529-1537 |g extent:9 |a Randomized comparison of interferon α and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II) prolongation of survival by the combination of interferon α and hydroxyurea |
| 856 | 4 | 0 | |u https://doi.org/10.1038/sj.leu.2403006 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/2403006 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220513 | ||
| 993 | |a Article | ||
| 994 | |a 2003 | ||
| 998 | |g 115699325 |a Queißer, Wolfgang |m 115699325:Queißer, Wolfgang |d 60000 |d 61200 |e 60000PQ115699325 |e 61200PQ115699325 |k 0/60000/ |k 1/60000/61200/ |p 13 | ||
| 998 | |g 172629551 |a Reiter, Andreas |m 172629551:Reiter, Andreas |d 60000 |d 61200 |e 60000PR172629551 |e 61200PR172629551 |k 0/60000/ |k 1/60000/61200/ |p 8 | ||
| 998 | |g 1051897661 |a Metzgeroth, Georgia |m 1051897661:Metzgeroth, Georgia |d 60000 |d 61200 |e 60000PM1051897661 |e 61200PM1051897661 |k 0/60000/ |k 1/60000/61200/ |p 5 | ||
| 998 | |g 1107039339 |a Hochhaus, Andreas |m 1107039339:Hochhaus, Andreas |p 4 | ||
| 998 | |g 1255399929 |a Berger, Ute |m 1255399929:Berger, Ute |d 60000 |d 61200 |e 60000PB1255399929 |e 61200PB1255399929 |k 0/60000/ |k 1/60000/61200/ |p 2 | ||
| 998 | |g 1037003489 |a Hehlmann, Rüdiger |m 1037003489:Hehlmann, Rüdiger |d 60000 |d 61200 |e 60000PH1037003489 |e 61200PH1037003489 |k 0/60000/ |k 1/60000/61200/ |p 1 |x j | ||
| 999 | |a KXP-PPN180171715X |e 4133905792 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"titleAlt":[{"title":"Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II)"}],"language":["eng"],"person":[{"given":"Rüdiger","role":"aut","display":"Hehlmann, Rüdiger","family":"Hehlmann"},{"given":"Ute","role":"aut","family":"Berger","display":"Berger, Ute"},{"role":"aut","given":"M.","display":"Pfirrmann, M.","family":"Pfirrmann"},{"family":"Hochhaus","display":"Hochhaus, Andreas","given":"Andreas","role":"aut"},{"role":"aut","given":"Georgia","family":"Metzgeroth","display":"Metzgeroth, Georgia"},{"display":"Maywald, O.","family":"Maywald","given":"O.","role":"aut"},{"display":"Hasford, J.","family":"Hasford","given":"J.","role":"aut"},{"family":"Reiter","display":"Reiter, Andreas","given":"Andreas","role":"aut"},{"role":"aut","given":"D. K.","family":"Hossfeld","display":"Hossfeld, D. K."},{"display":"Kolb, H.-J.","family":"Kolb","given":"H.-J.","role":"aut"},{"display":"Löffler, H.","family":"Löffler","role":"aut","given":"H."},{"family":"Pralle","display":"Pralle, H.","given":"H.","role":"aut"},{"display":"Queißer, Wolfgang","family":"Queißer","role":"aut","given":"Wolfgang"},{"family":"Griesshammer","display":"Griesshammer, M.","role":"aut","given":"M."},{"role":"aut","given":"C.","family":"Nerl","display":"Nerl, C."},{"display":"Kuse, R.","family":"Kuse","role":"aut","given":"R."},{"display":"Tobler, A.","family":"Tobler","given":"A.","role":"aut"},{"family":"Eimermacher","display":"Eimermacher, H.","role":"aut","given":"H."},{"given":"A.","role":"aut","family":"Tichelli","display":"Tichelli, A."},{"role":"aut","given":"C.","display":"Aul, C.","family":"Aul"},{"role":"aut","given":"M.","family":"Wilhelm","display":"Wilhelm, M."},{"display":"Fischer, J. T.","family":"Fischer","role":"aut","given":"J. T."},{"family":"Perker","display":"Perker, M.","role":"aut","given":"M."},{"display":"Scheid, C.","family":"Scheid","given":"C.","role":"aut"},{"role":"aut","given":"M.","display":"Schenk, M.","family":"Schenk"},{"given":"J.","role":"aut","family":"Weiß","display":"Weiß, J."},{"display":"Meier, C. R.","family":"Meier","given":"C. R.","role":"aut"},{"role":"aut","given":"S.","family":"Kremers","display":"Kremers, S."},{"given":"L.","role":"aut","family":"Labedzki","display":"Labedzki, L."},{"role":"aut","given":"T.","display":"Schmeiser, T.","family":"Schmeiser"},{"given":"H.-P.","role":"aut","family":"Lohrmann","display":"Lohrmann, H.-P."},{"role":"aut","given":"H.","family":"Heimpel","display":"Heimpel, H."}],"id":{"doi":["10.1038/sj.leu.2403006"],"eki":["180171715X"]},"name":{"displayForm":["R. Hehlmann, U. Berger, M. Pfirrmann, A. Hochhaus, G. Metzgeroth, O. Maywald, J. Hasford, A. Reiter, D.K. Hossfeld, H.-J. Kolb, H. Löffler, H. Pralle, W. Queißer, M. Griesshammer, C. Nerl, R. Kuse, A. Tobler, H. Eimermacher, A. Tichelli, C. Aul, M. Wilhelm, J.T. Fischer, M. Perker, C. Scheid, M. Schenk, J. Weiß, C.R. Meier, S. Kremers, L. Labedzki, T. Schmeiser, H.-P. Lohrmann, H. Heimpel and the German CML-Study Group"]},"physDesc":[{"extent":"9 S."}],"recId":"180171715X","relHost":[{"language":["eng"],"part":{"volume":"17","extent":"9","year":"2003","pages":"1529-1537","issue":"8","text":"17(2003), 8, Seite 1529-1537"},"title":[{"title":"Leukemia","subtitle":"normal and malignant hemopoiesis ; a peer-reviewed journal","title_sort":"Leukemia"}],"pubHistory":["Nachgewiesen 11.1997 -"],"note":["Gesehen am 15.03.04"],"origin":[{"dateIssuedDisp":"1997-","publisher":"Springer Nature ; Stockton Press ; Nature Publ. Group","dateIssuedKey":"1997","publisherPlace":"London ; Basingstoke [u.a.] ; Basingstoke"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Randomized comparison of interferon α and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II) prolongation of survival by the combination of interferon α and hydroxyureaLeukemia","physDesc":[{"extent":"Online-Ressource"}],"recId":"32046699X","id":{"issn":["1476-5551"],"zdb":["2008023-2"],"eki":["32046699X"]}}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 13.05.2022"],"origin":[{"dateIssuedKey":"2003","dateIssuedDisp":"29 July 2003"}],"title":[{"title":"Randomized comparison of interferon α and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II)","subtitle":"prolongation of survival by the combination of interferon α and hydroxyurea","title_sort":"Randomized comparison of interferon α and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II)"}]} | ||
| SRT | |a HEHLMANNRURANDOMIZED2920 | ||